- Curaleaf's actions and comments reflect its objective: to acquire, at the lowest price possible, Aurora's market-leading EU-GMP facilities and global medical cannabis platform.
- Curaleaf's description of Aurora's business performance does not reflect our recently reported quarterly results and stated European medical cannabis strategy.
- Comments by Curaleaf's CEO failed to present the facts; Aurora has engaged with Curaleaf since June 2026, including as recently as Aug. 12, 2026.
- Questions about the offer or would like to stay informed? Contact Kingsdale Advisors toll-free at 1-800-749-9052 within North America, call or text 416-623-4172 or at [email protected].
[PRESS RELEASE] – EDMONTON, Alberta, Aug. 19, 2026 – Aurora Cannabis Inc., the Canadian-based leading global medical cannabis company, confirmed that Curaleaf Holdings Inc. has commenced an unsolicited takeover bid for all of the issued and outstanding common shares of the company at a stated implied consideration of US$4 per Aurora Share, consisting of 0.3463 subordinate voting shares of Curaleaf plus US$0.75 in cash per Aurora share (the "offer"). We note that the offer includes a cap on the value of the consideration of US$5 per Aurora Share, which is a lower price than Aurora Shares have traded as recently as Dec. 18, 2025.
Miguel Martin, executive chairman and CEO of Aurora, said, "The strong shareholder support demonstrated at our 2026 AGM reinforces our commitment to the long-term strategy we are executing. We believe Curaleaf made a strategic decision to make its offer public to pressure our shareholders into making a short-term decision for the benefit of Curaleaf shareholders. We will not do that. We are building this company for the long term and will always do what is right for Aurora shareholders.
"Contrary to assertions by Curaleaf, our door is always open to those that see value in our company. Aurora has been in dialogue with Curaleaf going back to June 22, 2026, and as recently as Aug. 12, 2026. Their objective is to acquire Aurora's highly strategic EU-GMP facilities and leading medical cannabis platforms at the lowest price possible, thereby depriving Aurora shareholders of any current and future value they generate.”
The offer follows an announcement by Curaleaf on Aug. 11, 2026, of its intention to make an offer for Aurora. At that time, Aurora confirmed that it received letters from Curaleaf dated June 23, 2026, and July 7, 2026, outlining proposals to acquire the Aurora shares. The June 23, 2026, letter contained no proposed financial terms and the July 7, 2026, letter included no detail regarding the mix of cash and share consideration being proposed by Curaleaf.
The company expects to provide a more comprehensive response to Aurora shareholders in a timely manner.
Take No Action on Offer
Aurora shareholders are advised to take NO action on the offer until the board of directors of Aurora has made a formal recommendation to shareholders. The offer will remain open for a minimum of 105 days, allowing Aurora shareholders until at least Dec. 1, 2026, to consider their options.
The board has formed a special committee of independent directors. The special committee will consider the offer with its advisers before making a recommendation to the board. Aurora shareholders will be notified of the board's formal recommendation through a news release and directors' circular within 15 days, in accordance with applicable securities laws.
Advisers
Aurora has retained the following leading industry advisers:
- Legal counsel to Aurora's special committee is Torys LLP.
- Legal counsel to the company includes Stikeman Elliott LLP and Paul, Weiss, Rifkind, Wharton & Garrison LLP.
- Fort Capital Partners is the company's financial adviser, and ICR is the company's communications counsel.
- Kingsdale Advisors is the company's strategic adviser and information agent.
Shareholder Assistance
Aurora shareholders with questions about the offer or who would like to stay informed may contact Kingsdale Advisors, the company's strategic adviser and information agent:
Toll-Free (within North America): 1-800-749-9052
Call or Text: 416-623-4172
Email: [email protected]
Shareholders should take NO action at this time. Shareholders should wait until the board has provided its formal recommendation regarding the offer.
